Clinical trials: Pulmonary Diseases
Chronic Obstructive Pulmonary Disease
A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease
This study is a multi-center, randomized, double-blind, placebo-controlled Phase II clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM326 in subjects with moderate to Severe…
- Trial name
- NCT07418736
- Testing
- CM326 dose 1, CM326 dose 2
- Where
- China
- Volunteers
- 318 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Alpha1-Antitrypsin Deficiency
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran…
- Trial name
- NCT05677971
- Testing
- Fazirsiran Injection
- Where
- 89 sites in United States, Australia and 17 more
- Volunteers
- 160 people
- Sponsor
- Takeda
Chronic Thromboembolic Pulmonary Hypertension
A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension (PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension (CTEPH) and the observed efficacy of other…
- Trial name
- SELECT (NCT03689244)
- Testing
- Selexipag
- Where
- 162 sites in United States, Argentina and 29 more
- Volunteers
- 128 people
- Sponsor
- Actelion
Infections, Streptococcal
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.
Three dose primary vaccination of healthy infants between 6 to 16 weeks of age at the time of the first vaccination against Streptococcus pneumonia, Neisseria meningitidis and Haemophilus influenzae type b.
- Trial name
- NCT00334334
- Testing
- Pneumococcal (vaccine)
- Where
- 66 sites in Germany, Poland and 1 more
- Volunteers
- 1,572 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Allergic Rhinitis Due to Grass Pollens
Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate
This trial is an exploratory randomised, parallel-group, double-blind, placebo- controlled, national, single-centre trial. The trial will be initiated before 2013 grass pollen season and subjects will be randomised in September…
- Trial name
- NCT01854736
- Testing
- Grazax
- Where
- 2 sites in Spain
- Volunteers
- 51 people
- Sponsor
- ALK-Abelló A/S
Asthma
Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)
The aim of the present study is to investigate the efficacy and safety of ciclesonide on lung function and safety. Ciclesonide will be inhaled at one dose level once daily, using an inhaler device with or without spacer.
- Trial name
- NCT00163436
- Testing
- Ciclesonide
- Where
- 66 sites in Canada, France and 4 more
- Volunteers
- 450 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- NCT01054885
- Testing
- FF Inhalation Powder, FF/GW642444 Inhalation Powder, GW642444 Inhalation Powder
- Where
- 149 sites in United States, Argentina and 7 more
- Volunteers
- 1,226 people
- Sponsor
- GlaxoSmithKline
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
COVID-19
A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
This is a phase 2/3, multicenter, randomized, placebo-controlled, observer-blind study assessing the safety, tolerability, immunogenicity, and efficacy of prophylactic hAd5-S-Fusion+N-ETSD against COVID-19.
- Trial name
- NCT06022224
- Testing
- hAd5-S-Fusion+N-ETSD
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
Asthma
A Single Dose Study to Assess the Regional Absorption and Bioavailability of 100mg GSK2190915A
GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor that attenuates the production of leukotrienes through the blockage of the first step in the leukotriene pathway, 5-lipoxygenase (5-LO) activation.
- Trial name
- NCT01318980
- Testing
- GSK2190915 100mg milled tablet, [14C] radiolabelled GSK2190915 solution, GSK2190915 100mg milled tablet administered to the proximal small bowel.
- Where
- United Kingdom
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Study In Airway Physiology In Children SERETIDE DISKUS ® Inhlaer and FLIXOTIDE® Inhaler Are Trademarks of GSK Group of Companies.
Comparison of two asthma treatments by lung function measures.
- Trial name
- NCT00169546
- Testing
- Salmeterol/fluticasone propionate, Fluticasone propionate
- Where
- 2 sites in New Zealand, United Kingdom
- Volunteers
- 64 people
- Sponsor
- GlaxoSmithKline
Cancer
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors
Heat shock protein 90 (Hsp90) is a chemical in the body that is involve in the promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90.
- Trial name
- NCT01892046
- Testing
- SNX-5422
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Esanex Inc.
Malignant Melanoma, Carcinoma, Non-Small-Cell Lung
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
First-in-human study to assess safety, tolerability, PK, and preliminary activity of PF-07284890 as a single agent and in combination with binimetinib in participants with BRAF V600-mutated advanced solid tumor malignancies with…
- Conditions
- Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms
- Trial name
- NCT04543188
- Testing
- PF-07284890, Binimetinib, Midazolam
- Where
- 45 sites in United States, Canada and 1 more
- Volunteers
- 65 people
- Sponsor
- Pfizer
Non Small Cell Lung Cancer
Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer
This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without radiation therapy in participants with NSCLC.
- Trial name
- NCT03438318
- Testing
- CMP-001, Atezolizumab, Radiation Therapy
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Regeneron Pharmaceuticals
COVID-19
JINZHEN for Treatment of Mild to Moderate COVID-19
JINZHEN is a botanical drug that contains eight chemical constituents extracted from plant, mineral and animal origin raw materials.
- Trial name
- NCT05092503
- Testing
- JINZHEN Granules for Oral Solution
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Lianyungang Kanion Group, Ltd.
HIV, Pneumonia
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
The purpose of this study is to learn about how well a vaccine (Prevnar 13, PCV13) works in preventing disease in adults with HIV. The diseases studied are pneumonia. Mostly the ones caused by the bacteria - pneumococcus.
- Conditions
- HIV, Pneumonia, Infections, Pneumococcal
- Trial name
- NCT05794191
- Testing
- Vaccine Administration
- Where
- United States
- Volunteers
- 350,399 people
- Sponsor
- Pfizer
Pneumonia
Telithromycin, Treating Adult Outpatients With Mild to Moderate Community-acquired Pneumonia (CAP) in High Bacterial Resistance Areas
Demonstrate efficacy of telithromycin over single-agent oral antibiotics usually prescribed by local guidelines ("usual care") for treating adult outpatients with mild to moderate community-acquired pneumonia (CAP) in high…
- Trial name
- NCT00538018
- Testing
- Telithromycin
- Volunteers
- 978 people
- Sponsor
- Sanofi
Venous Thromboembolism
Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty
Venous thromboembolic events (VTE), either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty.
- Trial name
- ACOR (NCT01984190)
- Where
- 10 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Asthma
Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)
To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.
- Trial name
- NCT00751413
- Testing
- Comparator: MK0633
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Pneumonia, Respiratory Tract Diseases
Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine
Infections with Streptococcus pneumoniae often cause serious health problems, especially for infants and the elderly.Failure to cover all polysaccharide types is an even greater problem with adults than with children.
- Conditions
- Pneumonia, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- PⅠCTPV (NCT04087460)
- Testing
- Protein based pneumococcal vaccine(Low dose), Protein based pneumococcal vaccine(Middle dose), Protein based pneumococcal vaccine(High dose)
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.